Summary
-
Gilead Sciences (GILD) shows strong technical buy signals, with a 19.60% gain since Trend Seeker's buy signal on 1/27 and a 50.31% gain in the last year.
The Barchart Brief: Your FREE insider update on the biggest news stories and investing trends, delivered midday The company offers a diverse portfolio of medicines for HIV, COVID-19, liver diseases, oncology, and more, with significant collaborations enhancing its pipeline.
Analysts are bullish with 15 strong buy ratings, expecting earnings to increase by 71.99% this year and 4.86% next year, despite a slight revenue dip.
GILD trades above key moving averages, has a P/E of 24.82, a dividend yield of 2.70%, and strong support at $112.92, making it a compelling buy.